Bright Minds Biosciences (DRUG) Enterprise Value (2021 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Enterprise Value data on file, last reported at -$226.0 million in Q1 2026.

• Quarterly Enterprise Value fell 481.39% year-over-year to -$226.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$226.0 million (down 481.39% YoY) and the FY2025 annual result came in at -$60.3 million, down 1316.87% from the prior year.
• Enterprise Value eased to -$226.0 million in Q1 2026, from -$64.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$4.3 million in Q3 2024 to a low of -$226.0 million in Q1 2026.
• A 5-year average of -$31.6 million and a median of -$8.3 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 61.92% — and 2025, when it tumbled 1316.87%.
• Tracing DRUG's Enterprise Value over 5 years: stood at -$8.3 million in 2022, then jumped by 39.57% to -$5.0 million in 2023, then slumped by 725.19% to -$41.5 million in 2024, then slumped by 54.14% to -$64.0 million in 2025, then tumbled by 253.17% to -$226.0 million in 2026.
• The last three Enterprise Value figures came in at -$226.0 million (Q1 2026), -$64.0 million (Q4 2025), and -$60.3 million (Q3 2025), per Business Quant data.